FBIO — Fortress Biotech Full Year 2025 Earnings

Fortress just dropped a loaded earnings report. The monetization machine is firing.

The headlines.

Cyprium sold its Rare Pediatric Disease Priority Review Voucher for $205 million in gross proceeds after ZYCUBO got FDA approval for Menkes disease. Fortress expects to receive at least $100 million from Cyprium through dividends, intercompany debt, interest, and accrued expenses. Plus Cyprium gets tiered royalties and up to $128 million in sales milestones from Sentynl. One subsidiary, one approval, one PRV sale, and that's $333 million in total potential value created.

Checkpoint was acquired by Sun Pharma for ~$355 million upfront plus ~$60 million CVR. Fortress got $28 million upfront, up to $4.8 million more from the CVR, and a 2.5% royalty on UNLOXCYT net sales. That's a permanent revenue stream from an oncology drug that launched in January 2026.

Baergic was acquired by Axsome. Avenue (Fortress subsidiary) gets 74% of all future milestone and royalty payments, including up to $79 million in sales milestones and mid-to-high single-digit royalties.

Crystalys raised a $205 million Series A to take dotinurad into Phase 3 for gout. Fortress subsidiary Urica holds equity and gets a 3% royalty on future net sales.

The financials are turning.

Net loss collapsed from $55.9 million to $1.9 million. That's nearly breakeven. Revenue up to $63.3 million from $57.7 million, driven by Journey Medical's dermatology portfolio hitting $61.2 million in product sales. R&D dropped from $56.9 million to $11.9 million as programs got monetized or partnered out. Cash at $79.4 million, up from $57.3 million year over year. Oaktree debt paid down to $15 million.

The pipeline is still deep.

Dotinurad in Phase 3 for gout. Triplex CMV vaccine in Phase 2. Avenue just licensed ATX-04 (clenbuterol) from Duke University for Pompe disease, planning FDA meeting in 2026 for a potential single pivotal trial. Journey Medical's Emrosi launched for rosacea with Phase 3 data published in JAMA Dermatology.

This is Fortress doing what Fortress does. Build subsidiaries, advance them, monetize them. PRV sales, acquisitions by larger pharma, royalty streams, milestone payments. The model creates multiple shots on goal and multiple revenue streams from each one. $205 million PRV sale, $355 million Checkpoint acquisition, $205 million Crystalys Series A, $79 million in potential Avenue milestones. All from one holding company.

The stock is running today and now you know why.